Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 11:00 AM ET Company Participants Adam Lenkowsky - CCO Conference Call Participants Chris Shibutani - Goldman Sachs Operator Hey, it’s the start of the year. Welcome to 2024. Anyway, my name is Chris Shibutani. I'm a member of the Goldman Sachs healthcare team. We are deeply grateful for the teams that were able to join us for this conference this very early date this year, and obviously, the point ...

The S&P 500 closed out a strong year, up more than 20% for 2023. For investors looking for the best dividend stocks in the New Year and beyond, we recommend companies with durable competitive advantages and growth potential.In addition, substantial dividends help provide an additional return. Investors looking for high-quality dividend stocks should consider companies with high profitability and dividends that are sufficiently covered.With that in mind, let’s look at three top dividend stocks for 2024 and b ...

BALA CYNWYD, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. RayzeBio, Inc. (Nasdaq – RYZB) Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash transaction valued at approximate ...

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (“EMA”) has validated its marketing authorization application (“MAA”) for the next-generation tyrosine kinase inhibitor (“TKI”) repotrectinib.The MAA is seeking approval of the candidate for the treatment for ROS1 TKI-naïve and pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (“NSCLC”) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive lo ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI) repotrectinib as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive locally advanced ...

Mananya Kaewthawee Bristol-Myers Squibb (NYSE:BMY) is an American pharmaceutical company and one of the leaders in the oncology and cardiovascular markets. Thesis Since the end of 2022, the company's share price has fallen more than 36% before reaching the strong support level that caused a trend reversal in previous years. Before discussing the investment theses that make Bristol-Myers Squibb an attractive investment opportunity, I'd like to highlight the main reasons for the substantial decline in its pri ...

Key PointsBristol Myers Squibb plans to acquire Karuna Therapeutics for $14 billion. The company also expanded its psychiatric and neurological portfolio.It also offered $4.1 billion for cancer drug start-up RayzeBio.5 stocks we like better than Bristol-Myers SquibbBristol Myers Squibb Company NYSE: BMY is on a buying spree, announcing two acquisitions in less than a week. On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equ ...

Fusion Pharmaceuticals Inc.’s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. Bristol Meyers Squibb Co. BMY, -1.61% announced plans Tuesday to acquire Rayze Bio Inc. RYZB, +100.85% for $4.1 billion. Meanwhile Eli Lilly & Co.’s LLY, ...

BALA CYNWYD, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. RayzeBio, Inc. (Nasdaq – RYZB) Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash transaction valued at approximate ...